MedTrace Logo

The Value of PSMA-PET Compared With Multi-parametric MRI in the Detection Prostate Lesions

NCT03174054 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2017-06-02

No results posted yet for this study

Summary

Prostate cancer is a common disease in men. In prostate 35% of biopsies, usually done due to increased PSA levels or clinical suspicion, are false negative, despite malignancy.

Multi-parametric prostate MRI detects malignant neoplasm lesions better than other imaging devices.

A sonar-guided prostate biopsy based on multi-parametric MRI images improves detection of malignancy. Ga68 PSMA-PET test uses a radioactive marker that binds to the prostate's cells and is shown to be a primary prostate tumor site in addition to metastasis.

We believe that the combination of measures from a single Ga68 PSMA and multi-parametric MRI test can lead to further improvement in malignancy, better biopsy guidance, and optimal treatment for the patient.

Conditions

Interventions

PROCEDURE

Biopsy

Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.

Sponsors & Collaborators

  • Assuta Medical Center

    lead OTHER

Principal Investigators

  • David Groshar, MD · Head of nuclear medicine unit in Assuta Medical Centers

Eligibility

Min Age
40 Years
Max Age
95 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2019-01-01
Completion
2019-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03174054 on ClinicalTrials.gov